Jee Youngmee
Institut Pasteur Korea, Gyunggi-do, Republic of Korea.
Glob Health Med. 2021 Oct 31;3(5):288-292. doi: 10.35772/ghm.2021.01057.
In 2015, the World Health Organization (WHO) has set the goal of eliminating hepatitis C by reducing incidence of chronic viral hepatitis and related mortality by 2030 with the interim target of achieving 30% prevalence reduction by 2020. While The global prevalence of hepatitis C is known to be around 1.6%, the prevalence of hepatitis C in South Korea is 0.5-0.6% based on hepatitis C virus (HCV) antibody-positive rate. Although HCV antibody test has been included in the Annual National Health and Nutrition Survey in South Korea since 2012, a national initiative to eliminate hepatitis C was initiated by small clinic-related hepatitis C outbreaks in 2015-2016. These outbreaks caused by inappropriate use of syringes in 2015-2016 prompted the revision of hepatitis C reporting and control strategies in Korea following long-term discussion on including the HCV antibody test in the National Health Screening at a certain age. Since June 3, 2017, all hepatitis C cases should be reported to the Korea Disease Control Agency (KDCA). A pilot study for early detection of hepatitis C was conducted for the 56 years old population from September 1 to October 31 in 2020 by temporarily including HCV Ab in the National Health Screening followed by HCV RNA testing for HCV antibody positive cases. The final decision to include HCV antibody test in National Health Screening will be made based on results of the pilot study in 2020. To eliminate hepatitis B & C by 2030 in South Korea, the KDCA established a comprehensive viral hepatitis control and management system in 2020 with the interim goal of achieving an antibody positive rate of 0.3% and treatment rate of 90% by 2025.
2015年,世界卫生组织(WHO)设定了到2030年消除丙型肝炎的目标,即通过降低慢性病毒性肝炎的发病率和相关死亡率来实现这一目标,其中期目标是到2020年将患病率降低30%。已知丙型肝炎的全球患病率约为1.6%,而根据丙型肝炎病毒(HCV)抗体阳性率,韩国丙型肝炎的患病率为0.5-0.6%。尽管自2012年以来,HCV抗体检测已被纳入韩国年度国民健康与营养调查,但2015-2016年小型诊所相关的丙型肝炎疫情引发了韩国消除丙型肝炎的全国性行动。2015-2016年因注射器使用不当导致的这些疫情,促使韩国在长期讨论将HCV抗体检测纳入特定年龄的国民健康筛查后,修订了丙型肝炎报告和控制策略。自2017年6月3日起,所有丙型肝炎病例都应向韩国疾病控制机构(KDCA)报告。2020年9月1日至10月31日,通过在国民健康筛查中临时纳入HCV抗体,随后对HCV抗体阳性病例进行HCV RNA检测,对56岁人群进行了丙型肝炎早期检测的试点研究。是否将HCV抗体检测纳入国民健康筛查的最终决定将基于2020年试点研究的结果。为了在2030年在韩国消除乙型和丙型肝炎,KDCA在2020年建立了全面的病毒性肝炎控制和管理系统,中期目标是到2025年实现抗体阳性率为0.3%,治疗率为90%。